JP2025102775A5 - - Google Patents

Info

Publication number
JP2025102775A5
JP2025102775A5 JP2025034340A JP2025034340A JP2025102775A5 JP 2025102775 A5 JP2025102775 A5 JP 2025102775A5 JP 2025034340 A JP2025034340 A JP 2025034340A JP 2025034340 A JP2025034340 A JP 2025034340A JP 2025102775 A5 JP2025102775 A5 JP 2025102775A5
Authority
JP
Japan
Prior art keywords
pharmaceutical combination
administering
antibody
dexamethasone
lenalidomide
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2025034340A
Other languages
English (en)
Japanese (ja)
Other versions
JP2025102775A (ja
Filing date
Publication date
Priority claimed from PCT/IB2020/051484 external-priority patent/WO2020170211A1/en
Application filed filed Critical
Publication of JP2025102775A publication Critical patent/JP2025102775A/ja
Publication of JP2025102775A5 publication Critical patent/JP2025102775A5/ja
Pending legal-status Critical Current

Links

JP2025034340A 2019-02-22 2025-03-05 Cd38に特異的に結合する抗体、レナリドミド、及びデキサメタゾンの組み合わせを用いて、新たに診断された多発性骨髄腫を治療する方法 Pending JP2025102775A (ja)

Applications Claiming Priority (10)

Application Number Priority Date Filing Date Title
US201962809070P 2019-02-22 2019-02-22
US62/809,070 2019-02-22
US201962829814P 2019-04-05 2019-04-05
US201962829804P 2019-04-05 2019-04-05
US201962829791P 2019-04-05 2019-04-05
US62/829,814 2019-04-05
US62/829,804 2019-04-05
US62/829,791 2019-04-05
PCT/IB2020/051484 WO2020170211A1 (en) 2019-02-22 2020-02-21 Methods of treating newly diagnosed multiple myeloma with a combination of an antibody that specifically binds cd38, lenalidomide and dexamethasone
JP2021549416A JP7721445B2 (ja) 2019-02-22 2020-02-21 Cd38に特異的に結合する抗体、レナリドミド、及びデキサメタゾンの組み合わせを用いて、新たに診断された多発性骨髄腫を治療する方法

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
JP2021549416A Division JP7721445B2 (ja) 2019-02-22 2020-02-21 Cd38に特異的に結合する抗体、レナリドミド、及びデキサメタゾンの組み合わせを用いて、新たに診断された多発性骨髄腫を治療する方法

Publications (2)

Publication Number Publication Date
JP2025102775A JP2025102775A (ja) 2025-07-08
JP2025102775A5 true JP2025102775A5 (cg-RX-API-DMAC7.html) 2026-01-09

Family

ID=72141407

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2021549416A Active JP7721445B2 (ja) 2019-02-22 2020-02-21 Cd38に特異的に結合する抗体、レナリドミド、及びデキサメタゾンの組み合わせを用いて、新たに診断された多発性骨髄腫を治療する方法
JP2025034340A Pending JP2025102775A (ja) 2019-02-22 2025-03-05 Cd38に特異的に結合する抗体、レナリドミド、及びデキサメタゾンの組み合わせを用いて、新たに診断された多発性骨髄腫を治療する方法

Family Applications Before (1)

Application Number Title Priority Date Filing Date
JP2021549416A Active JP7721445B2 (ja) 2019-02-22 2020-02-21 Cd38に特異的に結合する抗体、レナリドミド、及びデキサメタゾンの組み合わせを用いて、新たに診断された多発性骨髄腫を治療する方法

Country Status (6)

Country Link
US (1) US20200268847A1 (cg-RX-API-DMAC7.html)
EP (1) EP3927376A4 (cg-RX-API-DMAC7.html)
JP (2) JP7721445B2 (cg-RX-API-DMAC7.html)
CN (1) CN113727729A (cg-RX-API-DMAC7.html)
CA (1) CA3131064A1 (cg-RX-API-DMAC7.html)
WO (1) WO2020170211A1 (cg-RX-API-DMAC7.html)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9732154B2 (en) 2014-02-28 2017-08-15 Janssen Biotech, Inc. Anti-CD38 antibodies for treatment of acute lymphoblastic leukemia
US9603927B2 (en) 2014-02-28 2017-03-28 Janssen Biotech, Inc. Combination therapies with anti-CD38 antibodies
PE20171094A1 (es) 2014-12-04 2017-08-07 Janssen Biotech Inc Anticuerpos anti-cd38 para el tratamiento de la leucemia linfoblastica aguda
CR20170526A (es) 2015-05-20 2018-04-03 Janssen Biotech Inc ANTICUERPOS ANTI-CD38 PARA EL TRATAMIENTO DE AMILOIDOSIS DE CADENA LIGERA y OTRAS ENFERMEDADES MALIGNAS HEMATOLÓGICAS POSITIVAS PARA CD38
JP7027321B2 (ja) 2015-11-03 2022-03-01 ヤンセン バイオテツク,インコーポレーテツド 抗cd38抗体の皮下製剤及びその使用
WO2018002181A1 (en) 2016-06-28 2018-01-04 Umc Utrecht Holding B.V. TREATMENT OF IgE-MEDIATED DISEASES WITH ANTIBODIES THAT SPECIFICALLY BIND CD38
US11618787B2 (en) 2017-10-31 2023-04-04 Janssen Biotech, Inc. Methods of treating high risk multiple myeloma
WO2023209555A1 (en) 2022-04-26 2023-11-02 Aragon Pharmaceuticals, Inc. Approved drug products and methods for treating prostate cancer

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9732154B2 (en) * 2014-02-28 2017-08-15 Janssen Biotech, Inc. Anti-CD38 antibodies for treatment of acute lymphoblastic leukemia
US10213513B2 (en) * 2014-06-16 2019-02-26 Mayo Foundation For Medical Education And Research Treating myelomas
US10617757B2 (en) * 2014-08-08 2020-04-14 The Regents Of The University Of California Methods for treating multiple myeloma
US20170044265A1 (en) * 2015-06-24 2017-02-16 Janssen Biotech, Inc. Immune Modulation and Treatment of Solid Tumors with Antibodies that Specifically Bind CD38

Similar Documents

Publication Publication Date Title
JP2022523372A5 (cg-RX-API-DMAC7.html)
US12435138B2 (en) Immunotoxins, formulations thereof and their use in medicine
JP6278224B2 (ja) Pd−1アゴニストからなる自己免疫疾患治療剤
CN103533943B (zh) 由cd3特异性结合结构域导致的不良作用的预防
JP2025011257A (ja) Il-4r阻害剤の投与によるアレルギー処置方法およびアレルゲン特異的免疫療法の向上方法
TWI890481B (zh) 雙特異性抗體
JP2011504872A5 (cg-RX-API-DMAC7.html)
CN114173819A (zh) 通过施用il-4r拮抗剂治疗过敏和增强过敏原特异性免疫疗法的方法
JP7783183B2 (ja) 自己免疫障害における抗bcma治療
CN112969711B (zh) 使用克拉扎珠单抗脱敏和改善hla致敏患者中的肾脏移植
WO2023130081A1 (en) Method of treating a tumor with a combination of il-7 protein and vegf antagonist
Corbaux et al. Bullous diseases
Holle et al. ANCA-associated vasculitides: pathogenetic aspects and current evidence-based therapy
JP2024532438A5 (cg-RX-API-DMAC7.html)
US20240409656A1 (en) Methods of treating cd20 expressing b-cell cancers
Pham et al. Anti-interleukin-6 receptor therapy with tocilizumab for refractory pseudophakic cystoid macular edema
JP2024540304A5 (cg-RX-API-DMAC7.html)
JP2021505545A (ja) 造血細胞移植後の急性移植片対宿主病の発症のリスクを低減する方法
JP2024505923A5 (cg-RX-API-DMAC7.html)
JP2022537134A5 (cg-RX-API-DMAC7.html)
TW202019482A (zh) Htlv-1關聯性脊髓病(ham)之治療或預防劑、及ham之治療方法
Lee et al. High-Dose Intravenous Immunoglobulin to Treat Anti-Thymocyte Globulin Induction–Related BK Virus and Cytomegalovirus Infection in Patients with ABO-Incompatible Kidney Transplantation
Nachman et al. Developments in the immunotherapy of glomerular disease
Kedar et al. The role of intravenous immunoglobulins in the management of acute complex autoimmune conditions
Reichenbach A Sight for Sorre (l’s) Eyes